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Abstract
During the ‘Heart Failure and World Congress on Acute Heart Failure 2018’, many sessions and lectures focused on
cardio-oncology. This important ﬁeld of research is constantly growing, and therefore, a great amount of time during the
congress focused on it. Prevention and early recognition of side effects is very important in cancer patients. One of the most
common and potentially severe problems during antineoplastic therapy is cardiotoxicity. Hence, cardio-oncology is vital in
managing cancer patients. This paper will summarize the topics discussed in three main sessions and many additional
lectures throughout the ‘Heart Failure and World Congress on Acute Heart Failure 2018’. The covered topics included
pathophysiological mechanisms in the development of heart failure, risk factors, and early signs of cardiotoxicity detectable
with different circulating and imaging biomarkers, as well as cardioprotective treatments recommended by different
guidelines and position papers.
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Introduction
Cardio-oncology has become a large, expanding, and
important translational research area in modern medicine,
which is gaining rapid interest.1,2 Unfortunately,
chemotherapy, immunotherapy, radiation therapy, and
targeted therapies do not only effect cancer cells but also
effect cardiomyocytes and vascular cells.3 This can result
into minor, asymptomatic cardiac lesions, detectable with
circulating biomarkers or strain echocardiography, and also
into life-threatening conditions, like severe heart failure
(HF) or fulminant myocarditis.4,5 During the ‘Heart Failure
and World Congress on Acute Heart Failure 2018’, three full
scientiﬁc sessions as well as a number of additional lectures
within broader-subject sessions were dedicated to cardio-
oncology. The sessions aimed to help improve the
mechanistic understanding of cardiotoxicity as well as to
help clinicians with practical advice and treatment strate-
gies for cancer patients receiving potentially cardiotoxic on-
cology therapies. The congress was attended by 5881
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participants with >300 faculty members from 47 countries
and took place in Vienna, Austria, from May 26, 2018, to
May 29, 2018.
The ﬁrst cardio-oncology session started from pathophysi-
ological studies on the crosstalk of HF and cancer mecha-
nisms and then addressed how to approach cardiotoxicity in
cancer patients with preclinical markers of left ventricular
dysfunction (LVD) and in patients with conﬁrmed
cardiotoxicity. The second session discussed the prevalence
of cardiac dysfunction in cancer patients and the underlying
mechanisms. The third session reviewed the current recom-
mendations and gaps in evidence from the different
cardio-oncology guidelines and position statements. Addi-
tional lectures addressed cardiomyopathy in cancer and the
prevention of HF. Detailed listing of all sessions can be found
in Table S1.
Prevention and treatment of
cardiotoxicity
In modern-day oncology, cardiotoxicity is a growing problem1
and may be caused by cytotoxic chemotherapy, radiotherapy,
molecular targeted therapies, and immune-modulating
agents. In this scenario, active collaboration among
different medical specialists is required to integrate cardiac
imaging in cardio-oncology and to guide cardiovascular (CV)
monitoring (Figure 1). Various deﬁnitions of CV toxicity exist
depending upon the modalities used and whether clinical
symptoms are required. Regarding direct myocardial
toxicity, one common deﬁnition is a reduction of left ventric-
ular ejection fraction (LVEF) by >10 percentage points and
below the lower limit of normality (depending on local
standard operating procedure 50–55%).1 Cardiomyopathy in
cancer is becoming an increasingly recognized entity, as
Professor Dimitrios Farmakis from Athens, Greece, stressed
during a session dedicated to cardiomyopathies. Besides
anthracyclines, several additional agents may predispose to
the development of cardiomyopathies, while recent evidence
has shed some new light on the underlying pathophysiology.
Professor Farmakis emphasized that the two main challenges
of modern-day cardio-oncology are the integration of subtle
cardiac dysfunction surrogates into clinical practice and prov-
ing that cardio-active therapies are effective in preventing
cardiomyopathies in cancer patients.
Dr Teresa López-Fernández from Madrid, Spain, de-
scribed the established relevant risk factors for developing
cardiotoxicity: young (<18 years) or advanced age
(>65 years), simultaneous chemotherapy with other
potential cardiotoxic agents, previous radiation therapy,
chronic kidney disease, and established CV disease or risk
factors.1,6 Consequently, before initiation of anti-cancer
therapy treatment, it is important to assess the patient’s
individual risk of cardiotoxicity.7 Dr López-Fernández
highlighted the need to perform a baseline comprehensive
CV screening, including echocardiography assessment, to
exclude relevant cardiac problems and to optimize CV
therapy when needed8,9 (Figure 2). During and after cancer
treatment, cardiac biomarkers and new echocardiography
techniques are crucial in detecting LVD. Moreover, she
recommended using an automated quantiﬁcation of three-
dimensional ejection fraction, as it requires less time and
has a higher reproducibility.10 Another important question
is if cardiac monitoring just based on LVEF is enough.
Serum cardiac biomarkers and deformation parameters
have demonstrated to be more sensitive to detect
subclinical myocardial damage.1,11 An increase in cardiac
troponins or a relative reduction of global longitudinal
strain measured using speckle echocardiography by >15%
from baseline can help identifying patients at increased risk
of LVD with a good negative predictive value.1,12 In addi-
tion, if LVEF remains within the normal limits, but subclini-
cal damage is detected, Dr López-Fernández explained that
these patients may beneﬁt from additional cardioprotective
medication [angiotensin-converting enzyme (ACE)-inhibitors,
angiotensin receptor blockers, and/or beta-blockers] in
order to reduce the risk of future events.13 There is an
urgent need for randomized, double-blind controlled trials
to conﬁrm such beneﬁts because early HF treatment does
Figure 1 How to best deliver care.
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not always allow full recovery of ventricular function in
patients who have developed cardiotoxicity. Recent data
from Cardinale et al.14 conﬁrmed the need for early
cardiotoxicity diagnosis. In 2625 patients treated with
anthracyclines, with a prevalence of cardiotoxicity of 9%, it
was demonstrated that 98% of events occur within the ﬁrst
year of treatment. If cardiotoxicity occurred, beta-blocker
and ACE-inhibitor treatment were started and increased
to the highest tolerated dose. With this therapy, a partial
recovery of LVEF >50% was observed in 82% of patients,
but only 11% of patients achieved a full LVEF recovery. If
chronic HF develops nonetheless, it is associated with high
treatment costs15 and even on its own with disappointing 1
and 5 year survival rates of just 85 and 50%.16–19 A very
important part of modern-day research is the many different
multi-centre registries.20–23 They help us to better understand
the diverse problems24–26 and needs27–29 of our patients in
day-to-day life,30–32 monitor the quality of treatment,33–35
and identify new risk factors.36,37
Thus, the prevention of HF in cancer patients is very
important. Professor Alain Cohen-Solal from Paris, France,
addressed a study conducted in 273 low CV risk adult cancer
patients treated with low cumulative doses of anthracycline
chemotherapy called ‘The International CardioOncology
Society-One’ trial.38 There were two arms in the study: in
the ﬁrst, enalapril was only administered during chemother-
apy cycles if troponin levels increased, and in the second,
enalapril was administered before and during the entire
chemotherapy regime. With regard to the occurrence of
cardiotoxicity, both strategies resulted in similar results.
The authors concluded that the administration of enalapril
may be suitable for patients with an increase of troponin
values during anthracycline treatment, and Alain Cohen-Solal
emphasized that quick initiation of CV treatment after detec-
tion of subclinical LVD is vital in cancer patients.39 During a
session on prevention of HF, Professor Dimitrios Farmakis
addressed the interaction between HF and cancer, two enti-
ties that share several common risk factors, while the one
seems to increase the risk and worsen the outcome of
the other. Professor Farmakis grouped the strategies for the
prevention of HF in cancer into three main categories, includ-
ing ‘primordial prevention’ that is applicable before cancer
therapy in patients without any evidence of CV abnormalities,
‘primary prevention’ during cancer therapy in the presence of
subtle abnormalities such as increase in cardiac biomarkers or
worsening of left ventricular global longitudinal strain, and
‘secondary prevention’ during or after cancer therapy in the
presence of clear LVEF decline. All three approaches are
important in preventing HF in cancer patients.40
In the next congress presentation, Professor Thomas
Suter from Bern, Switzerland, discussed the alternative
clinical strategies to prevent cardiotoxicity. Professor
Suter explained that in some cases, also non-anthracycline
chemotherapies are an option, because these drugs are often
associated with a lower chance of cardiotoxicity during treat-
ment for high-risk patients but still can be effective in treating
cancer.1,41 Furthermore, to reduce the likelihood of LVD and
cardiotoxicity even further in some patients, he reviewed
using liposomal doxorubicin or concomitant dexrazoxane
(DEX).1,42 Newer options for cancer patients include targeted
therapies like trastuzumab, which can also be associated with
increased occurrence of cardiotoxicity.43 Treatment duration
of trastuzumab therapy is relevant to risk, and the beneﬁt
on HER2+ malignancies is signiﬁcant and must be remem-
bered when considering the risk:beneﬁt balance.44
The intersection between cardiology
and oncology
In patients with HF, many different co-morbidities can
inﬂuence the patients’ burden of disease.45,46 Common
Figure 2 Role of cardiac imaging in cardio-oncology.
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co-morbidities in patients with HF include iron deﬁciency,47,48
anaemia,49,50 liver dysfunction,51,52 chronic kidney dis-
ease,53,54 central sleep apnoea,55,56 chronic obstructive pul-
monary disease,57,58 sexual dysfunction,59,60 cachexia,61,62
sarcopenia,63,64 anorexia,65,66 and also cancer.67,68 Professor
Rudolf De Boer from Groningen, the Netherlands, presented
several studies, which have shown that cancer patients have
an increased risk to develop HF and that patients with both,
cancer and HF, demonstrate even worse prognosis than both
diseases alone.69,70 Interestingly, many cancers and HF share
similar risk factors like hypertension, smoking, diabetes, and
overweight.71–73 Rudolf De Boer concluded that HF per se
might promote tumour growth through inﬂammatory mecha-
nisms and circulating biochemical factors.74
The relatively frequent occurrence of HF in cancer patients,
which can lead to higher CV mortality75 and worse overall
prognosis, which is substantially attributed to anti-cancer
therapy,76 was discussed by Jochen Springer from Göttingen,
Germany. New theories are being investigated, and it has
been shown that cancer cells secrete factors (e.g. Ataxin-10)
that interfere with the metabolism of cardiomyocytes and
can cause wasting of the cardiac muscle,77 which may result
into a negative effect on prognosis.67 Furthermore, cardiac
muscle wasting in patients with lung, pancreatic, and gastro-
intestinal cancers has been shown recently.78,79 Elevated
circulating CV biomarkers, as predictors of mortality,80 as well
as impairments in the cardiopulmonary function,81 were also
found in chemotherapy naïve tumour patients. A recent
multivariate survival analysis in patients with colorectal,
pancreatic, and non-small lung cancer has shown that a
resting heart rate ≥75 beats per minute was independently
associated with worse survival.82 This might represent an
activation of the sympathetic nervous system like it has
already been observed in patients with HF.83 Consequently,
more research into this area is needed to better understand
systemic effects of cancer on the CV system.
Drs Javid Moslehi from Nashville, USA, and Carlo Gabriele
Tocchetti from Naples, Italy, compared classical and new
anti-cancer therapies and put an emphasis on different mech-
anisms of cardiotoxicity.84,85 Substantial research is currently
focused on understanding novel mechanisms of short-term
and long-term effects of anthracycline cardiotoxicity on the
heart muscle,86 and also newer therapies like immunother-
apies87 and target therapies (e.g. tyrosine kinase inhibitors
and trastuzumab)88 have been shown to be associated with
cardiac dysfunction in some patients.1 Recently, immune
checkpoint inhibitors have been shown to cause fulminant
myocarditis.89 Martin Štěrba from Hradec Králové, Czech
Republic, discussed the potential use of ACE-inhibitors/
angiotensin receptor blocker in prevention against chronic
anthracyclines cardiotoxicity referring to rabbit models90
and positive outcomes in the OVERCOME91 and PRADA92
trials. He also introduced the demanding necessity to
better analyse the antioxidant mechanisms of DEX: in fact, a
recent preclinical study93 hypothesized that the depletion of
topoisomerase 2β isoform, induced by DEX, might be the
key process involved in the DEX cardioprotection.94
Breast cancer in a patient with heart
failure
The management of HF in patients with breast cancer as a
co-morbidity was discussed in this session, with regard to
directives of the current guidelines. Dr Thomas Suter re-
ported two different approaches towards HF with reduced
ejection fraction and HF with preserved ejection fraction. In
the ﬁrst case, he said, it is recommended to avoid both
anthracyclines and trastuzumab if LVEF is <40%. In general,
chemotherapy drugs like taxanes and liposomal doxorubicin
may be used to minimize cardiotoxic side effects.95 When
the patient is affected by HF with preserved ejection fraction,
both anthracycline-based chemotherapy and targeted thera-
pies can sometimes still be used, but it is important to discuss
this in a multidisciplinary team and deﬁne appropriate
screening intervals for clinical monitoring of the patients.
Guidelines on anti-cancer treatment in patients with HF
were reviewed and analysed by Dr Alexander Lyon,
London, UK, and gaps in evidence commented by Dr
Markus Anker from Berlin, Germany. According to the cur-
rent European Society of Cardiology 2016 position paper on
cardiotoxicity,1 patients with higher risk (lifestyle risk fac-
tors, CV risk factors, current cardiac disease, and previous
cardiotoxic treatment) should be identiﬁed and surveilled,
for example, by regular clinical echocardiographic examina-
tion and cardiac biomarker screening. In 2012, the ‘Euro-
pean Society of Medical Oncology Cardiotoxicity
Guidelines’96 recommended frequent cardiac monitoring of
patients with high-dose doxorubicin chemotherapy or/and
pre-existing CV disease. In the ‘American Society of Clinical
Oncology Guidelines 2017’,97 the potential cardioprotective
effect of DEX in high-risk patients was positively docu-
mented, but its administration to cancer patients is associ-
ated with more frequent occurrence of leukopenia with
respect to a meta-analysis.98 Moreover, Cardinale et al.14
demonstrated that prompt cardioprotective intervention
with combination of ACE-inhibitors and beta-blockers is a
possible option for recovery of LVEF after early detection
of cardiac damage in echocardiograms. The recent position
paper from the Heart Failure Association Cardio-oncology
Study Group provides a contemporary review and frame-
work for the patient with HF who develops cancer.74
Markus Anker also discussed the neutral double-blind,
placebo-controlled CECCY99 trial that assessed the use of
carvedilol for the prevention of anthracycline toxicity in a
low CV risk cancer population and noted a short period
of follow-up time in this trial. He concluded that future
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trials in cardio-oncology should have longer follow-up
times, assess patients, who have a greater risk of
cardiotoxicity, and test relevant (higher) doses of
cardiotoxic chemotherapy.
Conclusions
During the ‘Heart Failure and World Congress on Acute Heart
Failure 2018’, three sessions focused on the quickly growing
ﬁeld of cardio-oncology, along with some additional lectures
during broader-themed sessions. The main focus of the
sessions was how to recognize and treat cardiotoxicity in
the clinical setting. More research including randomized
clinical studies is needed to learn more about the prevention
of cardiotoxicity and the long-term treatment of cancer
patients with cardiac dysfunction.
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